GLP-1 drugs will reshape the food and healthcare industries
HealthcareObesity drugs like Ozempic and Wegovy are achieving 15-20% weight loss with strong adherence. As prices fall and insurance coverage expands, adoption could reach 50M+ Americans by 2030, disrupting food, fitness, and medical device sectors.
Bull Case
- +
Clinical trials show sustained 20%+ weight loss with cardiovascular benefits
SELECT trial results, NEJM Nov 2023
- +
Medicare coverage expansion in 2025 opens 30M+ addressable market
CMS Final Rule 2025
- +
Manufacturing scale-up bringing costs down 40% by 2026
Novo Nordisk Q4 2024 Earnings Call
Bear Case
- -
Long-term side effects still unknown - muscle loss concerns emerging
JAMA meta-analysis on GLP-1 side effects
- -
High discontinuation rates (50%+ stop within 2 years) limit market size
Blue Cross Blue Shield adherence study
- -
Generic competition and oral alternatives could compress pricing by 2027
Morgan Stanley Pharma Research
Related Companies
LLY
Eli Lilly
Mounjaro/Zepbound franchise, fastest-growing GLP-1
NVO
Novo Nordisk
Ozempic/Wegovy market leader, 60%+ market share
PFE
Pfizer
Oral GLP-1 in Phase 3, potential disruptor
K
Kellanova
Snack food exposure - negative impact from reduced consumption
Key Catalysts
Mar 1, 2025
CMS Medicare Part D GLP-1 coverage begins
Jun 15, 2025
Eli Lilly oral GLP-1 Phase 3 results expected
Nov 1, 2025
Novo Nordisk next-gen weekly injection FDA decision
Disclaimer: For informational purposes only. Not investment advice. ThesisSwipe provides research and analysis but does not recommend any specific investment decisions. Always conduct your own research and consult with a qualified financial advisor before investing.
What's your take?
Your reaction is anonymous and helps us improve our theses
Discover More Theses
Get access to hundreds of investment ideas across 12 categories. Swipe, save, and share.
Save This Thesis
Create an account to save this thesis to your library and get notified about updates.
Sign Up NowFree forever. No credit card required.